Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2022-04-14

AUTHORS

S. R. Aravind, Kiran P. Singh, Grace Aquitania, Liliia Mogylnytska, Alsu G. Zalevskaya, Beata Matyjaszek-Matuszek, Karin Wernicke-Panten, My-Liên Nguyên-Pascal, Suzanne Pierre, Baerbel Rotthaeuser, Daniel Kramer, Bhaswati Mukherjee

ABSTRACT

IntroductionThis study compared the efficacy, safety, and immunogenicity of biosimilar insulin aspart premix SAR341402 Mix 70/30 (SARAsp-Mix) with European-approved insulin aspart mix 70/30 − NovoMix® 30 (NN-Mix) in people with type 1 (T1D) or type 2 diabetes (T2D).MethodsThis 26-week, open-label, phase 3 trial enrolled 402 people with T1D (n = 105) or T2D (n = 297) previously treated with premix insulin, who were randomized (1:1) to SARAsp-Mix (n = 204) or NN-Mix (n = 198).ResultsAfter 26 weeks, the least squares (LS) mean [median] change in HbA1c from baseline was similar in both treatment groups (SARAsp-Mix − 0.55% [− 0.60%]; NN-Mix − 0.64% [− 0.60%]). The LS mean difference for SARAsp-Mix versus NN-Mix was 0.08%, with the upper bound of the two-sided 95% confidence interval (− 0.139 to 0.303) slightly above the prespecified noninferiority margin of 0.3%. Noninferiority of SARAsp-Mix over NN-Mix was not demonstrated in the primary intent-to-treat analysis, primarily because of one extreme outlying value impacted by the COVID-19 pandemic in the SARAsp-Mix group. Noninferiority was achieved in all secondary analyses, including prespecified per-protocol supportive and COVID-19 sensitivity analyses, as well as post hoc sensitivity analyses. Other efficacy endpoints, insulin dosages, anti-insulin aspart antibody response, hypoglycemia, and adverse events were similar between groups.ConclusionsThe totality of evidence indicates that SARAsp-Mix provides effective glycemic control with a similar safety and immunogenicity profile to NN-Mix in people with diabetes treated for 26 weeks.Trial RegistrationEudraCT number 2017-000092-84. More... »

PAGES

1053-1071

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-022-01255-7

DOI

http://dx.doi.org/10.1007/s13300-022-01255-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1147105305

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35420397


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Columbia Asia Hospital, Bangalore, India", 
          "id": "http://www.grid.ac/institutes/grid.492708.0", 
          "name": [
            "Diabetes Care and Research Center, Diacon Hospital, Bangalore, India", 
            "Columbia Asia Hospital, Bangalore, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aravind", 
        "givenName": "S. R.", 
        "id": "sg:person.01156425431.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156425431.75"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Endocrinology, Fortis Hospital Mohali, Chandigarh, India", 
          "id": "http://www.grid.ac/institutes/grid.414986.6", 
          "name": [
            "Department of Endocrinology, Fortis Hospital Mohali, Chandigarh, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Singh", 
        "givenName": "Kiran P.", 
        "id": "sg:person.016302536424.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016302536424.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Davao Doctors Hospital, Davao City, Philippines", 
          "id": "http://www.grid.ac/institutes/grid.461105.7", 
          "name": [
            "Davao Doctors Hospital, Davao City, Philippines"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aquitania", 
        "givenName": "Grace", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Khmelnytskyi Regional Hospital, Khmelnytskyi, Ukraine", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Khmelnytskyi Regional Hospital, Khmelnytskyi, Ukraine"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mogylnytska", 
        "givenName": "Liliia", 
        "id": "sg:person.012202624556.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012202624556.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Endocrinology, First Pavlov State Medical University, St. Petersburg, Russia", 
          "id": "http://www.grid.ac/institutes/grid.412460.5", 
          "name": [
            "Department of Endocrinology, First Pavlov State Medical University, St. Petersburg, Russia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zalevskaya", 
        "givenName": "Alsu G.", 
        "id": "sg:person.011273171321.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011273171321.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Endocrinology, Medical University of Lublin, Lublin, Poland", 
          "id": "http://www.grid.ac/institutes/grid.411484.c", 
          "name": [
            "Department of Endocrinology, Medical University of Lublin, Lublin, Poland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matyjaszek-Matuszek", 
        "givenName": "Beata", 
        "id": "sg:person.01073771325.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073771325.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany", 
          "id": "http://www.grid.ac/institutes/grid.420214.1", 
          "name": [
            "Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wernicke-Panten", 
        "givenName": "Karin", 
        "id": "sg:person.01241414567.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01241414567.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi-Aventis Research and Development, Chilly-Mazarin, France", 
          "id": "http://www.grid.ac/institutes/grid.417924.d", 
          "name": [
            "Sanofi-Aventis Research and Development, Chilly-Mazarin, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nguy\u00ean-Pascal", 
        "givenName": "My-Li\u00ean", 
        "id": "sg:person.014010762573.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014010762573.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi-Aventis Research and Development, Chilly-Mazarin, France", 
          "id": "http://www.grid.ac/institutes/grid.417924.d", 
          "name": [
            "Sanofi-Aventis Research and Development, Chilly-Mazarin, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pierre", 
        "givenName": "Suzanne", 
        "id": "sg:person.016202073064.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016202073064.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany", 
          "id": "http://www.grid.ac/institutes/grid.420214.1", 
          "name": [
            "Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rotthaeuser", 
        "givenName": "Baerbel", 
        "id": "sg:person.016162055375.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016162055375.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany", 
          "id": "http://www.grid.ac/institutes/grid.420214.1", 
          "name": [
            "Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kramer", 
        "givenName": "Daniel", 
        "id": "sg:person.01154142027.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154142027.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi, 54 Rue La Bo\u00e9tie, 75008, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.417924.d", 
          "name": [
            "Sanofi, 54 Rue La Bo\u00e9tie, 75008, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mukherjee", 
        "givenName": "Bhaswati", 
        "id": "sg:person.014750372124.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014750372124.55"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1208/s12248-014-9599-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008471779", 
          "https://doi.org/10.1208/s12248-014-9599-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40268-018-0228-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101140162", 
          "https://doi.org/10.1007/s40268-018-0228-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11635490-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014783629", 
          "https://doi.org/10.2165/11635490-000000000-00000"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-04-14", 
    "datePublishedReg": "2022-04-14", 
    "description": "IntroductionThis study compared the efficacy, safety, and immunogenicity of biosimilar insulin aspart premix SAR341402 Mix\u00a070/30 (SARAsp-Mix) with European-approved insulin aspart mix\u00a070/30\u2009\u2212\u2009NovoMix\u00ae 30 (NN-Mix) in people with type\u00a01 (T1D) or type\u00a02 diabetes (T2D).MethodsThis 26-week, open-label, phase\u00a03 trial enrolled 402 people with T1D (n\u2009=\u2009105) or T2D (n\u2009=\u2009297) previously treated with premix insulin, who were randomized (1:1) to SARAsp-Mix (n\u2009=\u2009204) or NN-Mix (n\u2009=\u2009198).ResultsAfter 26\u00a0weeks, the least squares (LS) mean [median] change in HbA1c from baseline was similar in both treatment groups (SARAsp-Mix\u2009\u2212\u20090.55% [\u2212\u20090.60%]; NN-Mix\u2009\u2212\u20090.64% [\u2212\u20090.60%]). The LS mean difference for SARAsp-Mix versus NN-Mix was 0.08%, with the upper bound of the two-sided 95% confidence interval (\u2212\u20090.139 to 0.303) slightly above the prespecified noninferiority margin of 0.3%. Noninferiority of SARAsp-Mix over NN-Mix was not demonstrated in the primary intent-to-treat analysis, primarily because of one extreme outlying value impacted by the COVID-19 pandemic in the SARAsp-Mix group. Noninferiority was achieved in all secondary analyses, including prespecified per-protocol supportive and COVID-19 sensitivity analyses, as well as post hoc sensitivity analyses. Other efficacy endpoints, insulin dosages, anti-insulin aspart antibody response, hypoglycemia, and adverse events were similar between groups.ConclusionsThe totality of evidence indicates that SARAsp-Mix provides effective glycemic control with a similar safety and immunogenicity profile to NN-Mix in people with diabetes treated for 26\u00a0weeks.Trial RegistrationEudraCT number 2017-000092-84.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13300-022-01255-7", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "13"
      }
    ], 
    "keywords": [
      "prespecified noninferiority margin", 
      "open-label trial", 
      "effective glycemic control", 
      "premix insulin", 
      "efficacy endpoint", 
      "treat analysis", 
      "adverse events", 
      "glycemic control", 
      "similar safety", 
      "immunogenicity profile", 
      "antibody response", 
      "noninferiority margin", 
      "insulin dosage", 
      "IntroductionThis study", 
      "treatment groups", 
      "secondary analysis", 
      "diabetes", 
      "confidence intervals", 
      "noninferiority", 
      "COVID-19 pandemic", 
      "trials", 
      "weeks", 
      "group", 
      "safety", 
      "HbA1c", 
      "MethodsThis", 
      "Randomized", 
      "T2D", 
      "hypoglycemia", 
      "T1D", 
      "NovoMix", 
      "primary intent", 
      "immunogenicity", 
      "insulin", 
      "baseline", 
      "endpoint", 
      "efficacy", 
      "people", 
      "sensitivity analysis", 
      "dosage", 
      "pandemic", 
      "response", 
      "interval", 
      "evidence", 
      "differences", 
      "analysis", 
      "control", 
      "study", 
      "protocol", 
      "intent", 
      "events", 
      "post", 
      "profile", 
      "changes", 
      "outlying values", 
      "margin", 
      "types", 
      "Europeans", 
      "values", 
      "mix", 
      "phase", 
      "totality", 
      "least squares", 
      "squares"
    ], 
    "name": "Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M)", 
    "pagination": "1053-1071", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1147105305"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-022-01255-7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35420397"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-022-01255-7", 
      "https://app.dimensions.ai/details/publication/pub.1147105305"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T17:12", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_942.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13300-022-01255-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01255-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01255-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01255-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01255-7'


 

This table displays all metadata directly associated to this object as RDF triples.

237 TRIPLES      21 PREDICATES      92 URIs      81 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-022-01255-7 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Nec9ffd8b7f45472292d69cae338553e2
4 schema:citation sg:pub.10.1007/s40268-018-0228-x
5 sg:pub.10.1208/s12248-014-9599-2
6 sg:pub.10.2165/11635490-000000000-00000
7 schema:datePublished 2022-04-14
8 schema:datePublishedReg 2022-04-14
9 schema:description IntroductionThis study compared the efficacy, safety, and immunogenicity of biosimilar insulin aspart premix SAR341402 Mix 70/30 (SARAsp-Mix) with European-approved insulin aspart mix 70/30 − NovoMix® 30 (NN-Mix) in people with type 1 (T1D) or type 2 diabetes (T2D).MethodsThis 26-week, open-label, phase 3 trial enrolled 402 people with T1D (n = 105) or T2D (n = 297) previously treated with premix insulin, who were randomized (1:1) to SARAsp-Mix (n = 204) or NN-Mix (n = 198).ResultsAfter 26 weeks, the least squares (LS) mean [median] change in HbA1c from baseline was similar in both treatment groups (SARAsp-Mix − 0.55% [− 0.60%]; NN-Mix − 0.64% [− 0.60%]). The LS mean difference for SARAsp-Mix versus NN-Mix was 0.08%, with the upper bound of the two-sided 95% confidence interval (− 0.139 to 0.303) slightly above the prespecified noninferiority margin of 0.3%. Noninferiority of SARAsp-Mix over NN-Mix was not demonstrated in the primary intent-to-treat analysis, primarily because of one extreme outlying value impacted by the COVID-19 pandemic in the SARAsp-Mix group. Noninferiority was achieved in all secondary analyses, including prespecified per-protocol supportive and COVID-19 sensitivity analyses, as well as post hoc sensitivity analyses. Other efficacy endpoints, insulin dosages, anti-insulin aspart antibody response, hypoglycemia, and adverse events were similar between groups.ConclusionsThe totality of evidence indicates that SARAsp-Mix provides effective glycemic control with a similar safety and immunogenicity profile to NN-Mix in people with diabetes treated for 26 weeks.Trial RegistrationEudraCT number 2017-000092-84.
10 schema:genre article
11 schema:isAccessibleForFree true
12 schema:isPartOf N20dab9c2a72c4a57818b223a18b2877a
13 N364e671e86694f32980b8c20883f93f3
14 sg:journal.1044057
15 schema:keywords COVID-19 pandemic
16 Europeans
17 HbA1c
18 IntroductionThis study
19 MethodsThis
20 NovoMix
21 Randomized
22 T1D
23 T2D
24 adverse events
25 analysis
26 antibody response
27 baseline
28 changes
29 confidence intervals
30 control
31 diabetes
32 differences
33 dosage
34 effective glycemic control
35 efficacy
36 efficacy endpoint
37 endpoint
38 events
39 evidence
40 glycemic control
41 group
42 hypoglycemia
43 immunogenicity
44 immunogenicity profile
45 insulin
46 insulin dosage
47 intent
48 interval
49 least squares
50 margin
51 mix
52 noninferiority
53 noninferiority margin
54 open-label trial
55 outlying values
56 pandemic
57 people
58 phase
59 post
60 premix insulin
61 prespecified noninferiority margin
62 primary intent
63 profile
64 protocol
65 response
66 safety
67 secondary analysis
68 sensitivity analysis
69 similar safety
70 squares
71 study
72 totality
73 treat analysis
74 treatment groups
75 trials
76 types
77 values
78 weeks
79 schema:name Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M)
80 schema:pagination 1053-1071
81 schema:productId N6544333583db450bba996220cb43dbad
82 Na8b48986e7474265a10b6fcb12ec9409
83 Nf52c4b9066724b358ab5c617a9385c6c
84 schema:sameAs https://app.dimensions.ai/details/publication/pub.1147105305
85 https://doi.org/10.1007/s13300-022-01255-7
86 schema:sdDatePublished 2022-08-04T17:12
87 schema:sdLicense https://scigraph.springernature.com/explorer/license/
88 schema:sdPublisher N9ead73e8f5e942b586a88b464a6ac22c
89 schema:url https://doi.org/10.1007/s13300-022-01255-7
90 sgo:license sg:explorer/license/
91 sgo:sdDataset articles
92 rdf:type schema:ScholarlyArticle
93 N03f12a763cd94b0f8bbeb4451f211cf7 rdf:first sg:person.01073771325.69
94 rdf:rest N316fbfefb20a438997a886d2cad3c0f3
95 N20dab9c2a72c4a57818b223a18b2877a schema:volumeNumber 13
96 rdf:type schema:PublicationVolume
97 N316fbfefb20a438997a886d2cad3c0f3 rdf:first sg:person.01241414567.61
98 rdf:rest N3e1eeaa3de4e4f9b815667c136af208c
99 N364e671e86694f32980b8c20883f93f3 schema:issueNumber 5
100 rdf:type schema:PublicationIssue
101 N3e1eeaa3de4e4f9b815667c136af208c rdf:first sg:person.014010762573.15
102 rdf:rest N5d6c2196480d4824a7eee0d426610586
103 N3e6145e214dd4b4b89ab251ab3ad430f rdf:first sg:person.016302536424.88
104 rdf:rest N4c3411c075f444fd96f4ff9d80e07ca5
105 N4c3411c075f444fd96f4ff9d80e07ca5 rdf:first Nacc02f4e78de41a3938e23c5ccd3a5ab
106 rdf:rest Nbdc0d1fedb144c7cb309cb9d1a2ae08e
107 N5d6c2196480d4824a7eee0d426610586 rdf:first sg:person.016202073064.20
108 rdf:rest N8280d18aae224711a2d55c9a4cb958c9
109 N6544333583db450bba996220cb43dbad schema:name dimensions_id
110 schema:value pub.1147105305
111 rdf:type schema:PropertyValue
112 N8280d18aae224711a2d55c9a4cb958c9 rdf:first sg:person.016162055375.34
113 rdf:rest Nd7921507d7484740bdf84a9ac04305fb
114 N973b714c60a5413282805a69cc1da51f rdf:first sg:person.011273171321.30
115 rdf:rest N03f12a763cd94b0f8bbeb4451f211cf7
116 N9ead73e8f5e942b586a88b464a6ac22c schema:name Springer Nature - SN SciGraph project
117 rdf:type schema:Organization
118 Na8b48986e7474265a10b6fcb12ec9409 schema:name pubmed_id
119 schema:value 35420397
120 rdf:type schema:PropertyValue
121 Nacc02f4e78de41a3938e23c5ccd3a5ab schema:affiliation grid-institutes:grid.461105.7
122 schema:familyName Aquitania
123 schema:givenName Grace
124 rdf:type schema:Person
125 Nbdc0d1fedb144c7cb309cb9d1a2ae08e rdf:first sg:person.012202624556.78
126 rdf:rest N973b714c60a5413282805a69cc1da51f
127 Nd7921507d7484740bdf84a9ac04305fb rdf:first sg:person.01154142027.05
128 rdf:rest Nfdaab6f1ddf342bb9e107959aa509f5b
129 Nec9ffd8b7f45472292d69cae338553e2 rdf:first sg:person.01156425431.75
130 rdf:rest N3e6145e214dd4b4b89ab251ab3ad430f
131 Nf52c4b9066724b358ab5c617a9385c6c schema:name doi
132 schema:value 10.1007/s13300-022-01255-7
133 rdf:type schema:PropertyValue
134 Nfdaab6f1ddf342bb9e107959aa509f5b rdf:first sg:person.014750372124.55
135 rdf:rest rdf:nil
136 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
137 schema:name Medical and Health Sciences
138 rdf:type schema:DefinedTerm
139 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
140 schema:name Clinical Sciences
141 rdf:type schema:DefinedTerm
142 sg:journal.1044057 schema:issn 1869-6953
143 1869-6961
144 schema:name Diabetes Therapy
145 schema:publisher Springer Nature
146 rdf:type schema:Periodical
147 sg:person.01073771325.69 schema:affiliation grid-institutes:grid.411484.c
148 schema:familyName Matyjaszek-Matuszek
149 schema:givenName Beata
150 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073771325.69
151 rdf:type schema:Person
152 sg:person.011273171321.30 schema:affiliation grid-institutes:grid.412460.5
153 schema:familyName Zalevskaya
154 schema:givenName Alsu G.
155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011273171321.30
156 rdf:type schema:Person
157 sg:person.01154142027.05 schema:affiliation grid-institutes:grid.420214.1
158 schema:familyName Kramer
159 schema:givenName Daniel
160 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154142027.05
161 rdf:type schema:Person
162 sg:person.01156425431.75 schema:affiliation grid-institutes:grid.492708.0
163 schema:familyName Aravind
164 schema:givenName S. R.
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156425431.75
166 rdf:type schema:Person
167 sg:person.012202624556.78 schema:affiliation grid-institutes:None
168 schema:familyName Mogylnytska
169 schema:givenName Liliia
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012202624556.78
171 rdf:type schema:Person
172 sg:person.01241414567.61 schema:affiliation grid-institutes:grid.420214.1
173 schema:familyName Wernicke-Panten
174 schema:givenName Karin
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01241414567.61
176 rdf:type schema:Person
177 sg:person.014010762573.15 schema:affiliation grid-institutes:grid.417924.d
178 schema:familyName Nguyên-Pascal
179 schema:givenName My-Liên
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014010762573.15
181 rdf:type schema:Person
182 sg:person.014750372124.55 schema:affiliation grid-institutes:grid.417924.d
183 schema:familyName Mukherjee
184 schema:givenName Bhaswati
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014750372124.55
186 rdf:type schema:Person
187 sg:person.016162055375.34 schema:affiliation grid-institutes:grid.420214.1
188 schema:familyName Rotthaeuser
189 schema:givenName Baerbel
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016162055375.34
191 rdf:type schema:Person
192 sg:person.016202073064.20 schema:affiliation grid-institutes:grid.417924.d
193 schema:familyName Pierre
194 schema:givenName Suzanne
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016202073064.20
196 rdf:type schema:Person
197 sg:person.016302536424.88 schema:affiliation grid-institutes:grid.414986.6
198 schema:familyName Singh
199 schema:givenName Kiran P.
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016302536424.88
201 rdf:type schema:Person
202 sg:pub.10.1007/s40268-018-0228-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1101140162
203 https://doi.org/10.1007/s40268-018-0228-x
204 rdf:type schema:CreativeWork
205 sg:pub.10.1208/s12248-014-9599-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008471779
206 https://doi.org/10.1208/s12248-014-9599-2
207 rdf:type schema:CreativeWork
208 sg:pub.10.2165/11635490-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014783629
209 https://doi.org/10.2165/11635490-000000000-00000
210 rdf:type schema:CreativeWork
211 grid-institutes:None schema:alternateName Khmelnytskyi Regional Hospital, Khmelnytskyi, Ukraine
212 schema:name Khmelnytskyi Regional Hospital, Khmelnytskyi, Ukraine
213 rdf:type schema:Organization
214 grid-institutes:grid.411484.c schema:alternateName Department of Endocrinology, Medical University of Lublin, Lublin, Poland
215 schema:name Department of Endocrinology, Medical University of Lublin, Lublin, Poland
216 rdf:type schema:Organization
217 grid-institutes:grid.412460.5 schema:alternateName Department of Endocrinology, First Pavlov State Medical University, St. Petersburg, Russia
218 schema:name Department of Endocrinology, First Pavlov State Medical University, St. Petersburg, Russia
219 rdf:type schema:Organization
220 grid-institutes:grid.414986.6 schema:alternateName Department of Endocrinology, Fortis Hospital Mohali, Chandigarh, India
221 schema:name Department of Endocrinology, Fortis Hospital Mohali, Chandigarh, India
222 rdf:type schema:Organization
223 grid-institutes:grid.417924.d schema:alternateName Sanofi, 54 Rue La Boétie, 75008, Paris, France
224 Sanofi-Aventis Research and Development, Chilly-Mazarin, France
225 schema:name Sanofi, 54 Rue La Boétie, 75008, Paris, France
226 Sanofi-Aventis Research and Development, Chilly-Mazarin, France
227 rdf:type schema:Organization
228 grid-institutes:grid.420214.1 schema:alternateName Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany
229 schema:name Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany
230 rdf:type schema:Organization
231 grid-institutes:grid.461105.7 schema:alternateName Davao Doctors Hospital, Davao City, Philippines
232 schema:name Davao Doctors Hospital, Davao City, Philippines
233 rdf:type schema:Organization
234 grid-institutes:grid.492708.0 schema:alternateName Columbia Asia Hospital, Bangalore, India
235 schema:name Columbia Asia Hospital, Bangalore, India
236 Diabetes Care and Research Center, Diacon Hospital, Bangalore, India
237 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...